Literature DB >> 11588081

Drug points. Exacerbation of angina associated with latanoprost.

M Mitra1, B Chang, T James.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588081      PMCID: PMC57357          DOI: 10.1136/bmj.323.7316.783

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  3 in total

Review 1.  Prostaglandin analogues in the treatment of glaucoma.

Authors:  C Lindén; A Alm
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

2.  Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

Authors:  P G Watson
Journal:  Ophthalmology       Date:  1998-01       Impact factor: 12.079

3.  Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo.

Authors:  J Lai; H Jin; R Yang; J Winer; W Li; R Yen; K L King; F Zeigler; A Ko; J Cheng; S Bunting; N F Paoni
Journal:  Am J Physiol       Date:  1996-12
  3 in total
  5 in total

1.  First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2007-09

2.  Bimatoprost in the treatment of eyelash hypotrichosis.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2010-04-26

3.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

Review 4.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  The role of latanoprost in an inflammatory bowel disease flare.

Authors:  Sonali Paul; Martin Wand; Geoffrey T Emerick; James M Richter
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.